Compare Abbott Laboratories (ABT) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Sunrun Inc — how do they compare? Abbott Laboratories trades at $109.79 (market cap $187.95B), while Sunrun Inc trades at $9.99 (market cap $2.42B). The key difference: Abbott Laboratories is far larger — about 77.7× Sunrun Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals.
| ABT | RUN | |
|---|---|---|
Market Cap | $187.95B | $2.42B |
Sector | Health | Technology |
52-Week High | $136.62 | $21.41 |
52-Week Low | $82.57 | $9.38 |
Enterprise Value | $214.96B | $16.93B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Sunrun (RUN) trades at $10.19, up 3.24% today, but faces bearish technical signals despite strong earnings beats in recent quarters. The company shows solid valuation metrics with P/E of 6.82 and P/S of 0.78, though cash flow remains negative from operations. Recent news highlights mixed sentiment with Q2 earnings beating expectations but guidance cuts weighing on investor confidence.
The outlook remains cautious with analyst consensus bullish (62% buy ratings) and a $14.38 price target suggesting 41% upside potential. Key risks include negative operating cash flow, high debt levels, and competitive pressures in the solar industry. The stock offers value opportunity but requires careful monitoring of cash generation improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
